SCHEMBL6015474

SCHEMBL6015474

O=C(O)N1CC2CCCCC2C1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.58
HSD11B2 P80365 1/20 0.39
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
CHRNB2 P17787 3/20 0.35
CHRNA3 P32297 3/20 0.35
CHRNA4 P43681 3/20 0.35
CHRNB4 P30926 2/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNB3 Q05901 1/20 0.34
CHRNA6 Q15825 1/20 0.34
L3MBTL3 Q96JM7 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GAA P10253 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
CNR2 P34972 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022475 0.97 HSD11B1 (0.61) HSD11B1HSD11B2ALDH1A1TSHRCHRNB2
Hydrochloric Acid SCHEMBL6016934 0.97 HSD11B1 (0.56) HSD11B1HSD11B2ALDH1A1TSHRCHRNB2
SCHEMBL4830410 0.95 HSD11B1 (0.52) HSD11B1HSD11B2ALDH1A1TSHRCHRNB2
SCHEMBL28340951 0.95 HSD11B1 (0.52) HSD11B1HSD11B2ALDH1A1TSHRCHRNB2
Bromide SCHEMBL17009295 0.92 HSD11B1 (0.50) HSD11B1HSD11B2ALDH1A1TSHRCHRNB2
SCHEMBL30832718 0.89 HSD11B1 (0.44) HSD11B1HSD11B2CHRNB2CHRNA3CHRNA4
SCHEMBL2938030 0.86 HSD11B1 (0.54) HSD11B1L3MBTL3CNR2
SCHEMBL2824307 0.86 HSD11B1 (0.54) HSD11B1L3MBTL3CNR2
SCHEMBL8261093 0.86 HSD11B1 (0.45) HSD11B1HSD11B2ALDH1A1TSHRCHRNB2
SCHEMBL20958523 0.83 HSD11B1 (0.42) HSD11B1HSD11B2CHRNB2CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856735-B1 FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS UNIV NEW YORK (US) 2023-09-06 EP claimed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 WO disclosed
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
EP-1713779-A1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES Sanofi-Aventis Deutschland GmbH (DE) 2006-10-25 EP disclosed
EP-1615886-A1 [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS Warner-Lambert Company LLC (US) 2006-01-18 EP disclosed
WO-2005073199-A1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-08-11 WO disclosed
US-20050137215-A1 [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions GUZZO PETER R (US) 2005-06-23 US disclosed
WO-2004092134-A1 [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS WARNER-LAMBERT COMPANY LLC (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137215-A1 [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions PPIC, PRAP1, PRRC2C HSD11B1 2806/4885HSD11B2 2732/4885ALDH1A1 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.